Clinical trials: Depression NOS
Depression
Predicting Response to Depression Treatment (PReDicT)
Depression is a very common, serious and in some cases life-threatening condition, affecting around 350 million people globally.
- Trial name
- NCT02790970
- Testing
- PReDicT Test, Treatment as Usual
- Where
- 76 sites in France, Germany and 3 more
- Volunteers
- 913 people
- Sponsor
- P1vital Products Limited
Major Depressive Disorder, Depression
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression.
- Conditions
- Major Depressive Disorder, Depression, Healthy
- Trial name
- NCT06570369
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Healthy Volunteers
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
This Phase I/II clinical trial investigates the safety, tolerability, and potential therapeutic benefits of a novel sublingual formulation of 5-MeO-DMT.
- Trial name
- 5-MeO-DMT (NCT06816667)
- Testing
- BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Bipolar Depression
Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
The purpose of the study is to compare the sedation profile one hour after dose administration between Seroquel IR and Seroquel XR.
- Trial name
- NCT00926393
- Testing
- Quetiapine Immediate Release, Quetiapine Extended Release
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Respiratory Depression, Respiratory Failure
VitalThings Guardian Contactless Monitoring
This is a confirmatory study without any intervention. It is an uncontrolled, non-randomized and open-label study with measurements made with comparators, and it has a preset hypothesis for the primary endpoint.
- Conditions
- Respiratory Depression, Respiratory Failure, Deterioration, Clinical
- Trial name
- VINCENT (NCT06083272)
- Testing
- Vitalthings Guardian M10 fixed and M10 mobile
- Where
- Norway
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- VitalThings
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Study Of GW679769 In Major Depressive Disorder
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
- Trial name
- NCT00102492
- Testing
- GW679769
- Where
- 31 sites in United States, Canada
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stress
BALANCE Study: Beneficial Effects of A Diverse Prebiotic Fibre bLend on Affect, iNflammation, Cognition, and the Gut microbiomE
This clinical trial will investigate whether a powdered prebiotic fibre blend, at two doses, can improve perceived stress levels in healthy adults with mild-severe stress levels.
- Trial name
- BALANCE (NCT07477470)
- Testing
- Prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myota GmbH
Bipolar Disorder I or II
Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
- Trial name
- NCT00259272
- Testing
- olanzapine
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Depression, Postpartum, Depression, Post-Partum
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression
- Trial name
- NCT06979544
- Testing
- LPCN 1154A
- Where
- 18 sites in United States
- Volunteers
- 90 people
- Sponsor
- Lipocine Inc.
Depressive Episode, Bipolar 1 Depression
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
- Trial name
- NCT03543410
- Testing
- SEP-4199 200 mg, SEP-4199 400 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 344 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- Trial name
- NCT04442490
- Testing
- SAGE-217
- Where
- 39 sites in United States
- Volunteers
- 543 people
- Sponsor
- Biogen
Major Depressive Disorder
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder…
- Trial name
- NCT06223880
- Testing
- AXS-05, Bupropion
- Where
- 40 sites in United States
- Volunteers
- 350 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression in Remission
A Study of SDI-118 in Participants in Remission From Depression
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting…
- Trial name
- NCT05212116
- Testing
- SDI-118
- Where
- 3 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syndesi Therapeutics
Major Depressive Disorder, Anxiety
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.
- Trial name
- NCT00621270
- Testing
- BCI-540
- Where
- 16 sites in Canada
- Volunteers
- 115 people
- Sponsor
- BrainCells Inc.
Low Mood, Depressive Symptoms
The Effects of Bifidobacterium Longum 1714® in a Population With Low Mood
A randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of 8 weeks of supplementation with Bifidobacterium longum 1714® strain on Beck's Depression Inventory-II Score in adults who experience low mood.
- Trial name
- NCT04925440
- Testing
- Bifidobacterium longum 1714® strain
- Where
- Ireland
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- PrecisionBiotics Group Ltd.
Treatment Resistant Bipolar Depression
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression
This study is testing a new oral ketamine treatment called KET-AD in adults with treatment-resistant bipolar depression (TRBD). The study will look at how safe and tolerable the treatment is, and whether it may help improve…
- Trial name
- NCT07644767
- Testing
- KET-AD
- Volunteers
- 160 people
- Sponsor
- Neurocentrx Pharma Pty Ltd
Bipolar Depression, Suicidal Ideation
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SevereBD (NCT03396601)
- Testing
- Ketamine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- NeuroRx, Inc.
Depressive Disorder
28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
This study is being conducted to obtain information on the safety and tolerability of repeated doses of GW823296 for 28 days in healthy male and female subjects.
- Trial name
- NCT00511654
- Testing
- GW823296 tablet, Midazolam
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Social Phobia
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
- Trial name
- NCT00555139
- Testing
- GSK561679 tablet, GW876008 tablet, alprazolam
- Where
- 8 sites in Spain
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline